NASDAQ · CLYM
Climb Bio, Inc.
$10.20-$0.13 (-1.21%)
Climb Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 44.33% below the high.
Loading market information…
NASDAQ · BCYP · USD
Stock price
Quote as of Oct 25, 2021, 04:00 AM UTC. Cached market data; not a live quote.
Price history is currently unavailable.
Big Cypress Acquisition Corp.’s quoted price sits in the lower half of its reported 52-week range, 34.57% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Big Cypress Acquisition Corp. (BCYP) aims to acquire businesses and assets. This is accomplished through various strategies, including mergers, stock purchases, capital stock exchanges, reorganizations, or comparable business integrations. The company specifically targets life science enterprises situated within the United States and Israel. It was established in 2020 and operates from its headquarters in Miami Beach, Florida.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:36 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$10.20-$0.13 (-1.21%)
Climb Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 44.33% below the high.
$6.47$0.00 (0.0%)
Sinovac Biotech Ltd.: Healthcare · Medical - Pharmaceuticals.
$10.15+$0.02 (+0.2%)
iTeos Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.43% below the high.
$8.61+$0.02 (+0.23%)
Y-mAbs Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.55% below the high.
$3.65$0.00 (0.0%)
Revance Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.72% below the high.
$16.70+$0.05 (+0.3%)
Orchard Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 0.12% below the high.
$7.16+$0.01 (+0.14%)
G1 Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.42% below the high.
$8.05$0.00 (0.0%)
Vigil Neuroscience, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.62% below the high.
